Trials / Unknown
UnknownNCT03425565
A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- University College, London · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 3 weekly cycles of Pembrolizumab administered by IV |
Timeline
- Start date
- 2019-02-18
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
- First posted
- 2018-02-07
- Last updated
- 2024-04-12
Locations
5 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03425565. Inclusion in this directory is not an endorsement.